Cystic Fibrosis and Oxidative Stress: The Role of CFTR

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2022 Aug 26

PMID 36014562

Authors

Evelina Moliteo

Monica Sciacca

Antonino Palmeri

Maria Papale

Sara Manti

Giuseppe Fabio Parisi

Salvatore Leonardi

Affiliations

Soon will be listed here.

Abstract

There is substantial evidence in the literature that patients with cystic fibrosis (CF) have higher oxidative stress than patients with other diseases or healthy subjects. This results in an increase in reactive oxygen species (ROS) and in a deficit of antioxidant molecules and plays a fundamental role in the progression of chronic lung damage. Although it is known that recurrent infection-inflammation cycles in CF patients generate a highly oxidative environment, numerous clinical and preclinical studies suggest that the airways of a patient with CF present an inherently abnormal proinflammatory milieu due to elevated oxidative stress and abnormal lipid metabolism even before they become infected. This could be directly related to cystic fibrosis transmembrane conductance regulator (CFTR) deficiency, which appears to produce a redox imbalance in epithelial cells and extracellular fluids. This review aims to summarize the main mechanism by which CFTR deficiency is intrinsically responsible for the proinflammatory environment that characterizes the lung of a patient with CF.

Citing Articles

Body composition changes and clinical outcomes in pediatric cystic fibrosis during 24 months of lumacaftor ivacaftor therapy based on real-world data.

Imrei M, Keri A, Gacs E, Gonczi I, Melath M, Kosaras E Sci Rep. 2025; 15(1):2247.

PMID: 39824960 PMC: 11748628. DOI: 10.1038/s41598-025-86010-1.

Update on the Role of β2AR and TRPV1 in Respiratory Diseases.

Manti S, Gambadauro A, Galletta F, Ruggeri P, Piedimonte G Int J Mol Sci. 2024; 25(19).

PMID: 39408565 PMC: 11477158. DOI: 10.3390/ijms251910234.

Dysregulation of the Arachidonic Acid Pathway in Cystic Fibrosis: Implications for Chronic Inflammation and Disease Progression.

DOrazio S, Mattoscio D Pharmaceuticals (Basel). 2024; 17(9).

PMID: 39338347 PMC: 11434829. DOI: 10.3390/ph17091185.

Treatment of Acute and Long-COVID, Diabetes, Myocardial Infarction, and Alzheimer's Disease: The Potential Role of a Novel Nano-Compound-The Transdermal Glutathione-Cyclodextrin Complex.

Yutani R, Venketaraman V, Sheren N Antioxidants (Basel). 2024; 13(9).

PMID: 39334765 PMC: 11429141. DOI: 10.3390/antiox13091106.

A New Frontier in Cystic Fibrosis Pathophysiology: How and When Clock Genes Can Affect the Inflammatory/Immune Response in a Genetic Disease Model.

Carbone A, Vitullo P, Di Gioia S, Castellani S, Conese M Curr Issues Mol Biol. 2024; 46(9):10396-10410.

PMID: 39329970 PMC: 11430433. DOI: 10.3390/cimb46090618.

References

Sagel S, Khan U, Jain R, Graff G, Daines C, Dunitz J . Effects of an Antioxidant-enriched Multivitamin in Cystic Fibrosis. A Randomized, Controlled, Multicenter Clinical Trial. Am J Respir Crit Care Med. 2018; 198(5):639-647. PMC: 6118015. DOI: 10.1164/rccm.201801-0105OC. View

Guimbellot J, Taylor-Cousar J . Combination CFTR modulator therapy in children and adults with cystic fibrosis. Lancet Respir Med. 2021; 9(7):677-679. DOI: 10.1016/S2213-2600(21)00176-4. View

Manti S, Marseglia L, DAngelo G, Cuppari C, Cusumano E, Arrigo T . "Cumulative Stress": The Effects of Maternal and Neonatal Oxidative Stress and Oxidative Stress-Inducible Genes on Programming of Atopy. Oxid Med Cell Longev. 2016; 2016:8651820. PMC: 4967692. DOI: 10.1155/2016/8651820. View

Bergeron C, Cantin A . New Therapies to Correct the Cystic Fibrosis Basic Defect. Int J Mol Sci. 2021; 22(12). PMC: 8227161. DOI: 10.3390/ijms22126193. View

Manti S, Parisi G, Papale M, Marseglia G, Licari A, Leonardi S . Type 2 inflammation in cystic fibrosis: New insights. Pediatr Allergy Immunol. 2022; 33 Suppl 27:15-17. PMC: 9305411. DOI: 10.1111/pai.13619. View

Checa J, Martinez-Gonzalez I, Maqueda M, Mosquera J, Aran J . Genome-Wide RNAi Screening Identifies Novel Pathways/Genes Involved in Oxidative Stress and Repurposable Drugs to Preserve Cystic Fibrosis Airway Epithelial Cell Integrity. Antioxidants (Basel). 2021; 10(12). PMC: 8750174. DOI: 10.3390/antiox10121936. View

King J, Nichols A, Bentley S, Carr S, Davies J . An Update on CFTR Modulators as New Therapies for Cystic Fibrosis. Paediatr Drugs. 2022; 24(4):321-333. DOI: 10.1007/s40272-022-00509-y. View

Laselva O, Allegretta C, Di Gioia S, Avolio C, Conese M . Anti-Inflammatory and Anti-Oxidant Effect of Dimethyl Fumarate in Cystic Fibrosis Bronchial Epithelial Cells. Cells. 2021; 10(8). PMC: 8391758. DOI: 10.3390/cells10082132. View

Borcherding D, Siefert M, Lin S, Brewington J, Sadek H, Clancy J . Clinically-approved CFTR modulators rescue Nrf2 dysfunction in cystic fibrosis airway epithelia. J Clin Invest. 2019; 129(8):3448-3463. PMC: 6668689. DOI: 10.1172/JCI96273. View

10.

Wu G, Fang Y, Yang S, Lupton J, Turner N . Glutathione metabolism and its implications for health. J Nutr. 2004; 134(3):489-92. DOI: 10.1093/jn/134.3.489. View

11.

Farinha C, Callebaut I . Molecular mechanisms of cystic fibrosis - how mutations lead to misfunction and guide therapy. Biosci Rep. 2022; 42(7). PMC: 9251585. DOI: 10.1042/BSR20212006. View

12.

Di Pietro C, H Oz H, Murray T, Bruscia E . Targeting the Heme Oxygenase 1/Carbon Monoxide Pathway to Resolve Lung Hyper-Inflammation and Restore a Regulated Immune Response in Cystic Fibrosis. Front Pharmacol. 2020; 11:1059. PMC: 7372134. DOI: 10.3389/fphar.2020.01059. View

13.

Burgel P, Bellis G, Olesen H, Viviani L, Zolin A, Blasi F . Future trends in cystic fibrosis demography in 34 European countries. Eur Respir J. 2015; 46(1):133-41. DOI: 10.1183/09031936.00196314. View

14.

Dickerhof N, Pearson J, Hoskin T, Berry L, Turner R, Sly P . Oxidative stress in early cystic fibrosis lung disease is exacerbated by airway glutathione deficiency. Free Radic Biol Med. 2017; 113:236-243. DOI: 10.1016/j.freeradbiomed.2017.09.028. View

15.

De Boeck K . Cystic fibrosis in the year 2020: A disease with a new face. Acta Paediatr. 2020; 109(5):893-899. DOI: 10.1111/apa.15155. View

16.

Causer A, Shute J, Cummings M, Shepherd A, Gruet M, Costello J . Circulating biomarkers of antioxidant status and oxidative stress in people with cystic fibrosis: A systematic review and meta-analysis. Redox Biol. 2020; 32:101436. PMC: 7264436. DOI: 10.1016/j.redox.2020.101436. View

17.

Dickerhof N, Huang J, Min E, Michaelsson E, Lindstedt E, Pearson J . Myeloperoxidase inhibition decreases morbidity and oxidative stress in mice with cystic fibrosis-like lung inflammation. Free Radic Biol Med. 2020; 152:91-99. DOI: 10.1016/j.freeradbiomed.2020.03.001. View

18.

Favia M, de Bari L, Bobba A, Atlante A . An Intriguing Involvement of Mitochondria in Cystic Fibrosis. J Clin Med. 2019; 8(11). PMC: 6912654. DOI: 10.3390/jcm8111890. View

19.

Guerini M, Condro G, Friuli V, Maggi L, Perugini P . N-acetylcysteine (NAC) and Its Role in Clinical Practice Management of Cystic Fibrosis (CF): A Review. Pharmaceuticals (Basel). 2022; 15(2). PMC: 8879903. DOI: 10.3390/ph15020217. View

20.

Ziady A, Hansen J . Redox balance in cystic fibrosis. Int J Biochem Cell Biol. 2014; 52:113-23. PMC: 4035434. DOI: 10.1016/j.biocel.2014.03.006. View